MY142283A - Diagnosis and treatment of cancers and other conditions - Google Patents

Diagnosis and treatment of cancers and other conditions

Info

Publication number
MY142283A
MY142283A MYPI20023310A MYPI20023310A MY142283A MY 142283 A MY142283 A MY 142283A MY PI20023310 A MYPI20023310 A MY PI20023310A MY PI20023310 A MYPI20023310 A MY PI20023310A MY 142283 A MY142283 A MY 142283A
Authority
MY
Malaysia
Prior art keywords
probe
receptors
functional
treatment
antibody
Prior art date
Application number
MYPI20023310A
Other languages
English (en)
Inventor
Angus Gidley-Baird
Julian Alexander Barden
Original Assignee
Biosceptre Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR7430A external-priority patent/AUPR743001A0/en
Priority claimed from AUPR7431A external-priority patent/AUPR743101A0/en
Priority claimed from PCT/AU2002/000061 external-priority patent/WO2002057306A1/en
Application filed by Biosceptre Int Ltd filed Critical Biosceptre Int Ltd
Publication of MY142283A publication Critical patent/MY142283A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
MYPI20023310A 2001-09-03 2002-09-04 Diagnosis and treatment of cancers and other conditions MY142283A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR7430A AUPR743001A0 (en) 2001-09-03 2001-09-03 Diagnosis and treatment of irritable bowel syndrome
AUPR7431A AUPR743101A0 (en) 2001-09-03 2001-09-03 A cancer therapeutic
PCT/AU2002/000061 WO2002057306A1 (en) 2001-01-17 2002-01-17 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions

Publications (1)

Publication Number Publication Date
MY142283A true MY142283A (en) 2010-11-15

Family

ID=41706691

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20023310A MY142283A (en) 2001-09-03 2002-09-04 Diagnosis and treatment of cancers and other conditions

Country Status (9)

Country Link
JP (1) JP4467973B2 (https=)
CN (2) CN100497386C (https=)
AU (1) AU2002322192B2 (https=)
CA (1) CA2459348C (https=)
MY (1) MY142283A (https=)
NZ (2) NZ549019A (https=)
TW (1) TWI329648B (https=)
WO (1) WO2003020762A1 (https=)
ZA (1) ZA200402630B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
WO2004053426A1 (en) * 2002-12-05 2004-06-24 Kla-Tencor Technologies Corporation Apparatus and methods for detecting overlay errors using scatterometry
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
ATE542139T1 (de) * 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
CN101469352B (zh) * 2008-08-29 2011-12-21 苏州福英基因科技有限公司 一种早期子宫癌原位杂交检测试剂盒
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) * 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
EP2990800A1 (en) * 2014-08-29 2016-03-02 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Neprilysin as heartfailure (HF) prognostic marker
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
MX2019004410A (es) * 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
CN112166193A (zh) 2018-05-21 2021-01-01 生物权威（英国）有限公司 具有经修饰的接头结构域的嵌合抗原受体及其用途
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
CN114173811A (zh) * 2019-07-26 2022-03-11 生物权威(澳大利亚)有限责任公司 P2x7受体靶向治疗
BR112023020659A2 (pt) * 2021-04-08 2023-12-05 Biosceptre Aust Pty Ltd Métodos para controlar a atividade de célula imune

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
JP4384852B2 (ja) * 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置

Also Published As

Publication number Publication date
AU2002322192B2 (en) 2008-05-01
WO2003020762A1 (en) 2003-03-13
ZA200402630B (en) 2005-06-29
CN100497386C (zh) 2009-06-10
CN101445555B (zh) 2013-07-03
CN101445555A (zh) 2009-06-03
NZ565994A (en) 2010-02-26
JP2005513416A (ja) 2005-05-12
CA2459348A1 (en) 2003-03-13
JP4467973B2 (ja) 2010-05-26
CA2459348C (en) 2013-06-18
TWI329648B (en) 2010-09-01
CN1625565A (zh) 2005-06-08
NZ549019A (en) 2008-05-30

Similar Documents

Publication Publication Date Title
MY158262A (en) Diagnosis and treatments of cancers and other conditions
MY142283A (en) Diagnosis and treatment of cancers and other conditions
DE602004026014D1 (de) Verfahren zum Nachweis von medizinisch relevanten Zuständen in gelösten LBC-Proben
ATE337011T1 (de) Modifizierte psma-liganden und deren verwendung
GB0319376D0 (en) Histone modification detection
HUP0202532A2 (hu) Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása
DK1084145T3 (da) Antistoffer imod ED-B-domænet i fibronectin, konjugater indeholdende disse og anvendelse deraf til diagnosticering og behandling af tumorer og sygdomme forbundet med angiogenese
WO2004057336A3 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
MXPA03007786A (es) Amplificacion de sonda circular usando iniciadores de transferencia de energia.
SI1631312T1 (sl) Sestavki in postopki za terapijo vnetnih bolezni debelega äśrevesa
EP1884778A4 (en) METHOD FOR TESTING THE EFFECTIVENESS OF ANTITHROMBOTIC AGENT
ATE540979T1 (de) Leptinantagonist und verfahren zur quantitativen messung von leptin
CY1106688T1 (el) Αποτιμηση κοβαλαμινης
ATE418072T1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
TR200402517T1 (tr) HBV ilaç direnci tespit metotları
WO2008060376A3 (en) Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
DE50011181D1 (de) Nachweis des pyruvatkinase-isoenzyms im stuhl
WO2004074325A3 (en) Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
EP1476757A4 (en) METHOD AND KIT FOR PREDICTING CANCER
DE602004030824D1 (de) An der oberfläche befindliche campylobacter jejuni-polypeptide
Zavaleta et al. Partial filling multiple injection affinity capillary electrophoresis (PFMIACE) to estimate binding constants of receptors to ligands
BR0308117A (pt) Dìmeros de avidina eficazes em aumentar a concentração de biotina radioativa em radioimunoterapia pré-direcionada
WO2006066917A3 (en) Use of asc as a marker for colorectal cancer
EP0563244A4 (en) Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
DE60127935D1 (de) Verfahren zur diagnose der effektivität der xenotypischen antikörpertherapie